Batu Biologics Announces FDA Development Plans for ValloVax™ Angiogenesis-Targeting Cancer Vaccine

 Batu Biologics announced today FDA development plans for its patent-pending lead product, ValloVax™, a cancer immunotherapeutic “vaccine” that specifically targets the tumor blood vessels (endothelium). The vaccine is a “therapeutic vaccine” in that it will be used to stimulate the immune system of patients that already suffer from cancer. About Mestinon (Pyridostigmine Bromide) without prescription This is in contrast to conventional vaccines which are prophylactic, meaning that they are administered to prevent onset of disease.

“Currently the strongest evidence points to Govallo’s Vaccine, termed VG-1000, as working through inhibiting production of new blood vessels in tumors. We are aggressively pursuing this hypothesis as an underlying theme in our developmental experiments.”

ValloVax™ is comprised of isolated cells from the placenta, Metaglip (Glipizide-Metformin) with no Rx which are highly characterized and treated with a proprietary set of compounds to increase the immune system’s ability to respond to the vaccine.
“The physician-immunologist Dr. Valentin Govallo used his vaccine to treat over one hundred patients, most with incurable cancers, and reportedly had over 60% of his patients survive 10 years or longer. Subsequent to the publication of these data in his book, Immunology of Pregnancy and Cancer (Nova Publishers, 1993), numerous clinics outside of the US started to offer this therapy to cancer patients, with anecdotal reports of remissions in end stage cancer patients,” said Samuel Wagner, CEO of Batu Biologics. “Given advances in the field of immunotherapy of pregnancy and cancer, many of Dr. Govallo’s hypotheses regarding similarity between pregnancy and cancer were demonstrated correct. About Diovan Hct (Valsartan, Hydrochlorothiazide) with no prescription Unfortunately, no legitimate attempt has been made to manufacture this product in a manner consistent with FDA requirement.”
The company plans to achieve the following milestones
1. July 2014: Isolation, characterization of active cells in the placental preparation responsible for induction of anticancer immunity
2. September 2014: Animal efficacy experiments completed to identify optimum vaccine formulation. Buy Activelle with no Rx
3. December 2014: Completion of animal safety studies.
4. Q1 2015: Filing of IND to FDA for treatment of non-small stage lung cancer
“There are several paths that we are engaging to accelerate development of ValloVax™ , including leveraging existing data developed both by Batu Biologics, as well as an international collaborative network that we have established,” stated Andy Kim, VP of Scientific Research of Batu Biologics. Buy Vitamins online “Currently the strongest evidence points to Govallo’s Vaccine, termed VG-1000, as working through inhibiting production of new blood vessels in tumors. We are aggressively pursuing this hypothesis as an underlying theme in our developmental experiments.”
About Batu Biologics: Batu Biologics is a preclinical biopharmaceutical company focusing on developing and commercializing allogeneic cell therapies in the area of immune modulation. WebMD Consult Our products are centered around the idea of creating or breaking immune tolerance. The company is currently in the preclinical stages of drug development for its two flagship products: Immstem™ and Vallovax™. Batu Biologics has filed two provisional patents in the field of cancer immunotherapy and plans to significantly expand its IP in 2014. Recently, Batu Biologics published in the peer reviewed literature with Dr. Francesco Marincola, President of the Society for Immunotherapy of Cancer, as well as several other internationally-renowned immunotherapists,

NanoViricides, Inc. Demands Retraction of the Baseless and Inaccurate Libelous Article by an Anonymous Short Seller Posted on SeekingAlpha Website

NanoViricides, Inc. has demanded from Seeking Alpha the removal of a damaging, baseless and inaccurate article posted by a person who was shorting NNVC common stock.

“NanoViricides Demands Retraction of the Damaging Article by an Anonymous Short Seller Posted on SeekingAlpha Website”

It is obvious that the anonymous author of this article orchestrated the publication of this article in connection with a massive short position which this person was a major beneficiary of, possibly in collusion with others. Exelon (Rivastigimine) pills The article was clearly designed to manipulate the price of the Company’s common stock downwards for significant personal gains for the persons with short position in the stock including this anonymous author, at the expense of the Company’s shareholders. The article is pure libel, full of numerous false statements, inaccuracies, innuendos, is not based on any factual information about the Company, and twists many facts to fit the person’s motivation to cause a damaging view about the Company. The article has caused significant damage to the Company and its shareholders.
The Company has demanded retraction of the article from the SeekingAlpha website and disclosure of the identity of the anonymous person who posted it. Famvir (Famciclovir) The full text of the demand is posted on our website under the item: “NanoViricides Demands Retraction of the Damaging Article by an Anonymous Short Seller Posted on SeekingAlpha Website”.
The Company is also preparing a complaint to file with the Securities and Exchange Commission to request it to investigate this stock price manipulation.
NanoViricides, Inc. is fully prepared to seek appropriate legal action against parties involved in this libelous attack.
About NanoViricides:
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. Zofran (Ondansetron) without prescription The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Vitamins online Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. future Pharmaceuticals Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

Cubist Pharmaceuticals Prices $700 Million of Convertible Senior Notes

Cubist Pharmaceuticals, Inc. today announced the pricing of $700 million aggregate principal amount of convertible senior unsecured notes that will be issued in two series, with one series of $300 million aggregate principal amount maturing on September 1, 2018 (the 2018 notes) and the other series of $400 million aggregate principal amount maturing on September 1, 2020 (the 2020 notes and together with the 2018 notes, the Notes). The Notes are being offered and sold to qualified institutional buyers pursuant to Rule 144A under the Securities Exchange Act of 1933, as amended. Buy Trecator-sc (Ethionamide) without prescription Cubist has granted the underwriters an option to purchase up to an additional $50 million aggregate principal amount of each series of the Notes.
The 2018 Notes will bear interest at a rate of 1.125% per year and the 2020 Notes will bear interest at a rate of 1.875%, in each case, payable on March 1 and September 1 of each year, beginning on March 1, 2014. The Notes will not be redeemable prior to maturity. The Notes will be convertible, only during certain periods and subject to certain circumstances, into cash, shares of Cubist’s common stock, or a combination of cash and shares of Cubist’s common stock, at Cubist’s election. Buy Calan Sr (Verapamil) tabs online without prescription The initial conversion rate for each series of Notes is 12.1318 shares of Cubist’s common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $82.43 per share of Cubist’s common stock, representing an approximately 32.5% conversion premium based on the last reported sale price of Cubist’s common stock of $62.21 per share on September 4, 2013.
In connection with the pricing of the Notes, Cubist also entered into privately negotiated convertible note hedge transactions and warrant transactions with the initial purchasers or their respective affiliates (the option counterparties) in order to reduce the potential dilution with respect to shares of Cubist's common stock upon any conversion of the Notes and/or offset any cash payments Cubist is required to make in excess of the principal amount of converted Notes. Buy Calan (Verapamil) pills online without prescription If the initial purchasers exercise their option to purchase additional Notes, Cubist may enter into additional convertible note hedge and warrant transactions. The warrant transactions will have a dilutive effect with respect to Cubist's common stock to the extent that the market price per share of Cubist's common stock, as measured under the terms of the warrant transactions, exceeds the applicable strike price of the warrants, which is initially 55% higher than the last reported sale price of Cubist’s common stock on September 4, 2013.
Cubist estimates that the net proceeds of the offering will be $679 million (or $776 million if the initial purchasers’ options to purchase additional notes are exercised in full), after deducting the initial purchasers’ discounts and commissions, but prior to deducting estimated offering expenses. Cubist intends to use the majority of the net proceeds of the offering to fund its previously announced acquisition of Optimer Pharmaceuticals, Inc. and to pay $51 million to fund the cost of the convertible note hedge transactions (after such cost is partially offset by proceeds from the warrant transactions). Buy Vitamins online The remaining net proceeds from the offering will be used for general corporate purposes.
Cubist has been advised that, in connection with the convertible note hedge and warrant transactions, the option counterparties or their respective affiliates expect to purchase shares of Cubist’s common stock and/or enter into various derivative transactions with respect to Cubist’s common stock concurrently with or shortly after the pricing of the Notes. WebMD Help This activity could increase (or reduce the size of any decrease in) the market price of Cubist’s common stock or the Notes at that time. In addition, the option counterparties or their respective affiliates may, from time to time following the pricing of the Notes and prior to the maturity of the Notes, enter into or unwind various derivatives with respect to Cubist’s common stock and/or purchase or sell Cubist’s common stock in secondary market transactions (and are likely to do so during any observation period related to a conversion of Notes). This activity could also cause a decrease or avoid an increase in the market price of Cubist’s common stock or the Notes.
The offer and sale of the Notes are not being registered under the Securities Act of 1933, as amended, or any state securities laws. All Best Rx : Buy drugs online The Notes may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and any applicable state securities laws.
This news release does not constitute an offer to sell or a solicitation of an offer to buy the notes described herein, nor shall there be any sale of these notes, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the laws of such jurisdiction.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the estimated net proceeds of the offering and Cubist’s planned use of the net proceeds from the sale of the Notes. FDA Approved Rx : Online Pharmacy Forward-looking statements are based on current beliefs and expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including without limitation, whether or not Cubist will be able to consummate the offering and the hedge and warrant transactions on the timeline or with the terms anticipated, if at all, and, if consummated, that Cubist will also close its recently announced acquisition of Optimer Pharmaceuticals, Inc. on the anticipated timeline, or at all, so that it can use the proceeds of the offering as anticipated. Drugs Rx Guide : Buy drugs online In addition, management retains broad discretion with respect to the allocation of the net proceeds of this offering. You are cautioned not to place significant reliance on forward-looking statements. The information in this press release speaks only as of the date of this release, and Cubist undertakes no obligation to update or revise any forward-looking statement to reflect events or circumstances occurring after the date of this press release.

Baxter and JW Holdings Announce Exclusive Global Development and Commercialization Collaboration for Omega 3 Parenteral Nutrition Products

Baxter International Inc. and JW Holdings today announced that they have entered into an exclusive distribution and license agreement for parenteral nutritional products containing a novel formulation of omega 3 lipids. With this collaboration, Baxter will complement its leading global parenteral nutrition portfolio, and provide global commercial capabilities and clinical development.
Under the terms of the agreement, Baxter will have exclusive rights to co-develop and distribute the products globally, with the exception of Korea. Buy Vibramycin (Doxycycline) pills online without prescription The arrangement includes a $25 million up-front payment that will be recorded as a special pre-tax in-process research and development charge in the third quarter of 2013. Additionally, the agreement calls for payments totaling up to $10 million for the achievement of regulatory milestones, along with royalties on future product sales.
The agreement remains in effect for 10 years following the first product launch outside of Korea. The companies will share equally in the development costs and global clinical trials and registrations. JW Holdings will manufacture the products in its Dangjin, Korea facility. Buy Viagra Super Active (Sildenafil Citrate) tabs online without prescription Additionally, Baxter has specified rights to certain additional nutritional products that JW Holdings may develop or produce in the future.
“Lipids are an important part of nutrition therapy, particularly for those patients who rely on parenteral feeding for sole-source or supplemental nutrition,” said Robert M. Davis, president of Baxter’s Medical Products business. Buy Principen (Ampicillin) without prescription “Baxter’s collaboration with JW Holdings allows us to complement our existing parenteral nutrition product portfolio and provide clinicians with additional options to meet patients’ unique nutritional needs.”
“The agreement with Baxter expands our ability to help more patients benefit from parenteral nutritional products containing our novel formulation of omega 3 lipids,” said Gu Seo Park, chief operating officer of JW Holdings. Buy Vitamins online “Both companies are bringing unique technology and expertise to this collaboration, which also will create new opportunities for JW Holdings to grow and gain recognition globally.”
About Baxter
Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. BioLineRx Announces Pre-clinical Results Demonstrating the Safety of BL-7010, an Oral Treatment for Celiac Disease and Gluten Sensitivity As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.
About JW Holdings
JW Holdings operates as a holding company of JW Pharmaceutical which is one of the leading pharmaceutical companies in Korea. JW Group, since its foundation in 1945, has been leading therapeutic medicine industry in Korea with the business motto represented by “Respect for Life” and “Pioneering Spirit.” Drugs Rx Guide : Buy drugs online JW Group is committed to providing medicine and medical supplies in the areas including I.V. solution and circulatory, digestive, and urinary system treatments. The JW Holdings plant located in Dangjin is the largest medical manufacturing complex in Korea that supplies various medical products including non-PVC I.V. solutions and is equipped with a cutting-edge automated control system while satisfying international GMP standard.
This release includes forward-looking statements concerning a development and commercialization agreement between Baxter International Inc. and JW Holdings, including expectations with regard to the financial impact of such agreement on the company and future regulatory milestone payments. All Best Rx : Buy drugs online The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; FDA Approved Rx : Online Pharmacy actions of regulatory bodies and other governmental authorities; clinical trial results; changes in laws and regulations; product quality or patient safety issues; and other risks identified in Baxter's most recent filings on Form 10-K and other SEC filings. Baxter does not undertake to update its forward-looking statements.

Clinical Research Advantage Receives Silver Best in Biz Award for Executive Team of the Year

Clinical Research Advantage (CRA) received a national honor in this year’s Best in Biz Awards, the only independent business awards program judged by members of the press and industry analysts. CRA received the Silver Award for Executive Team of the Year.

“We are honored to receive this level of recognition from the Best in Biz Awards.”

Mark S. Hanley, Chief Executive Officer, and David Bruggeman, President and Chief Operating Officer, were recognized for their strategic vision and leadership in growing the company to become the largest and most therapeutically diverse integrated site network in the clinical trials industry.
“2012 has been an exciting year for Clinical Research Advantage. This year, the company expanded its operations while forging innovative partnerships that will continue to improve the quality of clinical trials,” said Bruggeman. Buy Furoxone (Furazolidone) pills online without prescription “We are honored to receive this level of recognition from the Best in Biz Awards.”
More than 400 entries were received in this year’s awards program, from a wide array of public and private companies of all sizes and from a variety of industries and regions in the U.S. and Canada.
Winners of Best in Biz Awards 2012 were determined by an independent panel of 32 judges from top-tier news, business and technology publications, as well as broadcast outlets and analyst firms, such as ABC, Businessweek, Computerworld, ECT News Network, Entrepreneur, eWeek, Examiner, Financial Times, Forbes, FOX News, Hartford Business Journal, IDG Ventures, IEEE Institute, Inc., Insight Media, King Features Syndicate, Lab Reviews, Network World, The News and Observer, PC Magazine, ReadWriteWeb, South Florida Business Journal, Tech-Gaming, Techtalk, Upstart Business Journal, USA Today and ZDNet.
About Clinical Research Advantage
Tempe, Arizona-based Clinical Research Advantage, Inc. (CRA) is a provider of a range of research services to pharmaceutical companies and clinical research organizations. As a leading trial management organization, CRA operates from 38 sites across 17 geographic markets nationwide, helping trial sponsors bring drugs to market more quickly and efficiently. Founded in 1992, CRA has successfully completed more than 1,800 clinical trials on behalf of its clients.